下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>
多维分析
公司估值 资金追踪 卖空分析
富途牛牛 > 行情 > PFE 辉瑞 > 关键指标
PFE 辉瑞
44.080
-0.490-1.10%
盘前价
43.620
-0.46-1.04%
显示同比
不显示
隐藏空行
(Q2)2022/07/03(Q1)2022/04/03(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-47.8% 88.6391 -60.12% 89.9172 -63.47% 86.3151 -63.47% 86.3151
Receivable Turnover(T)
39.7% 7.8685 70.33% 8.0067 66.44% 8.3763 66.44% 8.3763
Inventory Turnover(T)
113.59% 3.948 206.13% 3.968 238.5% 3.6037 238.5% 3.6037
Fixed Assets Turnover(T)
75.41% 6.8736 91.87% 6.3484 87.8% 5.6485 87.8% 5.6485
Total Asset Rate(T)
73.74% 0.5546 89% 0.5395 85.89% 0.4843 85.89% 0.4843
ROIC
111.8% 25.675% 109.58% 22.987% 111.85% 21.159% 111.85% 21.159%
ROE
89.55% 37.276% 98.31% 33.058% 105.66% 31.300% 105.66% 31.300%
ROA
111.27% 16.050% 112.7% 14.572% 119.04% 13.094% 119.04% 13.094%
FCF to Sales
-24.22% 28.082% 23.58% 34.385% 32.61% 36.745% 32.61% 36.745%
FCF to Net Income
-37.68% 97.038% 9.81% 127.305% 12.54% 135.898% 12.54% 135.898%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- 19.36% 24.277% -- --
ROA 5 Year Average
-- -- -- -- 22.47% 9.634% -- --
Average 5 Years ROIC
-- -- -- -- 20.91% 15.641% -- --
Profitability Ratios TTM
Gross Margin
-12.23% 62.182% -20.98% 60.352% -21.67% 62.084% -21.67% 62.084%
Operating Margin
29.52% 31.634% 23.1% 27.537% 19.09% 24.893% 19.09% 24.893%
Net Margin
21.6% 28.939% 12.54% 27.010% 17.84% 27.038% 17.84% 27.038%
EBITDA Margin
4.22% 0.3797% 3.37% 0.3691% 15.68% 0.3788% 15.68% 0.3788%
R & D Expense Ratio
-20.34% 14.530% -27.19% 15.290% -24.2% 17.010% -24.2% 17.010%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-22.09% 39.324% -16.02% 43.259% -20.16% 46.884% -20.16% 46.884%
Total Assets to Common Equity
-7.69% 223.936% -3.63% 223.043% -3.62% 235.070% -3.62% 235.070%
Debt to Asset Ratio
-17.55% 46.193% -23.89% 44.031% -20.97% 49.787% -20.97% 49.787%
Current Ratio
3.97% 1.423 -6.57% 1.3859 3.4% 1.3989 3.4% 1.3989
Quick Ratio
6.51% 1.0766 1.34% 1.0247 21.45% 1.0971 21.45% 1.0971
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- 304.57% 14.858% -- --
Revenue CAGR(5Y)
-- -- -- -- 398.18% 9.003% -- --
Net Income CAGR(3Y)
-- -- -- -- 208.92% 25.373% -- --
Net Income CAGR(5Y)
-- -- -- -- 273.66% 24.955% -- --
Dividend CAGR(3Y)
-- -- -- -- -20.63% 4.680% -- --
Dividend CAGR(5Y)
-- -- -- -- -14.46% 5.387% -- --
FCF 1 Year Growth
-- -- -- -- 871.14% 157.225% -- --
FCF CAGR(3Y)
-- -- -- -- 552.63% 29.887% -- --
FCF CAGR(5Y)
-- -- -- -- 832.31% 16.528% -- --
Currency Unit
美元美元美元美元

FY:Financial Year 年度报告,相当于上市公司向SEC披露的10-K文件。

Q:Quarter 季度报告,相当于上市公司向SEC披露的10-Q文件,其中Q1、Q2、Q3、Q4为单季报,跨度为3个月;Q6、Q9为累计季报,Q6为6个月,Q9为9个月。

环比数据来源于季报,环比 = (本期 - 上期)/上期 * 100%

公司概况 更多
辉瑞制药公司致力于医疗保健产品的发现、开发和生产,主要从事药品、疫苗和消费者医疗保健。它通过辉瑞创新健康(IH)和辉瑞基本健康(EH)部门运作。IH部门侧重于开发和商业化内科学、肿瘤学、炎症和免疫学、率病和消费者保健的药物和疫苗。EH部门参与开发和供应品牌仿制药、普通无菌注射产品、生物仿制药,以及选择品牌产品,包括抗感染药物。公司于1849年创立,总部设在纽约。
CEO: Bourla D.V.M., DVM, Ph.D., Albert
所属市场: 纽交所
上市日期: 1944/01/17
富途热股榜
美股港股沪深
交易热度搜索热度资讯热度
名称代码最新价涨跌幅

加载中...

自选
回到顶部